Updated Apr 1, 2025, 4:44 PM UTC
| Income Statement - Metric | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD, thousands) | 16,097.00 | 240,735 | 3,551 | 0.00 | 0.00 | 0.00 | 3,551 | 2,500 | ||||||||
| Research and Development Expenses (USD, thousands) | 99,855.00 | 353,188 | 116,491 | 101,122.00 | 152,431.00 | 135,826.00 | 505,870 | 137,002 | ||||||||
| General and Administrative Expenses (USD, thousands) | 24,572.00 | 92,549 | 23,605 | 25,069.00 | 23,710.00 | 26,377.00 | 98,761 | 26,910 | ||||||||
| Total Operating Expenses (USD, thousands) | 124,427.00 | 445,737 | 140,096 | 126,191.00 | 176,141.00 | 162,203.00 | 604,631 | 163,912 | ||||||||
| Operating Loss (USD, thousands) | (108,330.00) | (205,002) | (136,545) | (126,191.00) | (176,141.00) | (162,203.00) | (601,080) | (161,412) | ||||||||
| Interest Income (USD, thousands) | 3,885.00 | 15,299 | 2,802 | 6,250.00 | 6,498.00 | 7,170.00 | 22,720 | 7,602 | ||||||||
| Interest Expense (USD, thousands) | (5,262.00) | (18,326) | (5,367) | (7,244.00) | (5,094.00) | (14,647.00) | (32,352) | (21,646) | ||||||||
| Other, Net (USD, thousands) | 717.00 | 1,538 | 421 | 189.00 | 760.00 | (3,118.00) | (1,748) | 341 | ||||||||
| Total Other Expense (USD, thousands) | 660.00 | 1,489 | 2,144 | (5,093.00) | 2,164.00 | (10,595.00) | (11,380) | (13,703) | ||||||||
| Loss Before Income Tax Expense and Noncontrolling Interest (USD, thousands) | (108,990.00) | (206,491) | (138,689) | (126,996.00) | (173,977.00) | (172,798.00) | (612,460) | (175,115) | ||||||||
| Income Tax Expense (Benefit) (USD, thousands) | 2,025.00 | 2,784 | (3,313) | 0.00 | 0.00 | 546.00 | (2,767) | 103 | ||||||||
| Net Loss Including Noncontrolling Interest (USD, thousands) | (111,015.00) | (209,275) | (135,376) | (126,996.00) | (173,977.00) | (173,344.00) | (609,693) | (175,218) | ||||||||
| Net Loss Attributable to Noncontrolling Interest, Net of Tax (USD, thousands) | - | - | - | - | - | - | - | - | ||||||||
| Net Loss Attributable to Arrowhead Pharmaceuticals, Inc. (USD, thousands) | (109,679.00) | (205,275) | (132,864) | (125,300.00) | (170,793.00) | (170,536.00) | (599,493) | (173,085) | ||||||||
| Basic Net Loss Per Share Attributable to Arrowhead Pharmaceuticals, Inc. (USD) | (1.02) | (1.92) | (1.24) | (1.00) | (1.39) | (1.37) | (5.00) | (1.39) | ||||||||
| Diluted Net Loss Per Share Attributable to Arrowhead Pharmaceuticals, Inc. (USD) | (1.02) | (1.92) | (1.24) | (1.00) | (1.39) | (1.37) | (5.00) | (1.39) | ||||||||
| Weighted-average Shares Used in Calculating Basic Net Loss Per Share (thousands) | 153.00 | 106,750 | 107,415 | 7,892.00 | 2,953.00 | 1,524.00 | 119,784 | 124,848 | ||||||||
| Weighted-average Shares Used in Calculating Diluted Net Loss Per Share (thousands) | - | - | - | - | - | - | - | - | ||||||||
| Unrealized (Losses) Gains on Available-for-Sale Securities (USD, thousands) | - | (2,964) | 1,909 | 216.00 | 249.00 | 1,401.00 | 3,775 | (507) | ||||||||
| Foreign Currency Translation Adjustments (USD, thousands) | 153.00 | (122) | 58 | (56.00) | (141.00) | 4,336.00 | 4,197 | (106) | ||||||||
| Comprehensive Loss (USD, thousands) | (113,826.00) | (212,361) | (133,409) | (126,836.00) | (173,869.00) | (167,607.00) | (601,721) | (175,831) | ||||||||
| Total Other Income (Expense) (USD, thousands) | (660.00) | (1,489) | (2,144) | (805.00) | 2,164.00 | (10,595.00) | (11,380) | (13,703) | ||||||||
| Operating (Loss) Income (USD, thousands) | (108,330.00) | (205,002) | (136,545) | (126,191.00) | (176,141.00) | (162,203.00) | (601,080) | (161,412) | ||||||||
| (Loss) Income Before Income Tax (Benefit) Expense and Noncontrolling Interest (USD, thousands) | (108,990.00) | (206,491) | (138,689) | (126,996.00) | (173,977.00) | (172,798.00) | (612,460) | (175,115) | ||||||||
| Net (Loss) Income Including Noncontrolling Interest (USD, thousands) | (111,015.00) | (209,275) | (135,376) | (126,996.00) | (173,977.00) | (173,344.00) | (609,693) | (175,218) | ||||||||
| Net (Loss) Income Attributable to Arrowhead Pharmaceuticals, Inc. (USD, thousands) | (109,679.00) | (205,275) | (132,864) | (125,300.00) | (170,793.00) | (170,536.00) | (599,493) | (173,085) | ||||||||
| Basic Net (Loss) Income Per Share Attributable to Arrowhead Pharmaceuticals, Inc. (USD) | (1.02) | (1.92) | (1.24) | (1.00) | (1.39) | (1.37) | (5.00) | (1.39) | ||||||||
| Diluted Net (Loss) Income Per Share Attributable to Arrowhead Pharmaceuticals, Inc. (USD) | (1.02) | (1.92) | (1.24) | (1.00) | (1.39) | (1.37) | (5.00) | (1.39) | ||||||||
| Comprehensive (Loss) Income (USD, thousands) | (113,826.00) | (212,361) | (133,409) | (126,836.00) | (173,869.00) | (167,607.00) | (601,721) | (175,831) | ||||||||
| Change in Unrealized Losses on Available-for-Sale Securities (USD, thousands) | - | (2,964) | 1,909 | 216.00 | 249.00 | 1,401.00 | 3,775 | (507) | ||||||||
| Amortization (Accretion) of Note Premiums/Discounts (USD, thousands) | (987.00) | (2,017) | (835) | - | - | - | - | - | ||||||||
| Realized Loss on Investments (USD, thousands) | - | - | 80 | - | - | - | - | - | ||||||||
| Non-cash Interest Expense on Liability Related to the Sale of Future Royalties (USD, thousands) | 5,262.00 | 18,326 | 5,367 | - | - | - | - | - | ||||||||
| Other (USD, thousands) | 717.00 | 1,538 | 421 | 189.00 | 760.00 | (3,118.00) | (1,748) | 341 | ||||||||
| Stock-based Compensation (USD, thousands) | - | - | - | - | - | - | - | - | ||||||||
| Depreciation and Amortization (USD, thousands) | - | - | - | - | - | - | - | - | ||||||||
| Realized Gain on Investments (USD, thousands) | - | - | (80) | - | - | - | - | - | ||||||||
| Balance Sheet - Metric | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| Cash, Cash Equivalents and Restricted Cash [USD, thousands] | 110,891 | 110,891 | 58,215 | 127,704 | 69,399 | 102,685 | 102,685 | 53,889 | ||||||||
| Accounts Receivable [USD, thousands] | - | - | - | - | - | - | - | 2,500 | ||||||||
| Available-for-Sale Securities, at Fair Value [USD, thousands] | 292,735 | 292,735 | 162,064 | 395,410 | 367,272 | 578,276 | 578,276 | 499,046 | ||||||||
| Prepaid Expenses [USD, thousands] | 8,813 | 8,813 | 10,516 | 11,022 | 9,207 | 9,537 | 9,537 | 9,366 | ||||||||
| Other Current Assets [USD, thousands] | 7,082 | 7,082 | 7,104 | 7,514 | 4,184 | 4,973 | 4,973 | 5,735 | ||||||||
| Total Current Assets [USD, thousands] | 419,521 | 419,521 | 237,899 | 541,650 | 450,062 | 695,471 | 695,471 | 570,536 | ||||||||
| Property, Plant and Equipment, Net [USD, thousands] | 290,262 | 290,262 | 333,411 | 359,252 | 375,911 | 386,032 | 386,032 | 387,069 | ||||||||
| Intangible Assets, Net [USD, thousands] | 10,262 | 10,262 | 9,837 | 9,412 | 8,987 | 8,562 | 8,562 | 8,137 | ||||||||
| Right-of-Use Assets [USD, thousands] | 45,297 | 45,297 | 44,907 | 44,626 | 44,339 | 45,255 | 45,255 | 44,869 | ||||||||
| Other Assets [USD, thousands] | 210,218 | 210,218 | 232,210 | - | 4,460 | 4,482 | 4,482 | 3,083 | ||||||||
| Total Assets [USD, thousands] | 765,552 | 765,552 | 626,286 | 955,150 | 883,759 | 1,139,802 | 1,139,802 | 1,013,694 | ||||||||
| Accounts Payable [USD, thousands] | 35,866 | 35,866 | 4,460 | 8,521 | 26,550 | 11,388 | 11,388 | 14,457 | ||||||||
| Accrued Expenses [USD, thousands] | 39,763 | 39,763 | 46,604 | 37,055 | 47,899 | 63,017 | 63,017 | 59,401 | ||||||||
| Accrued Payroll and Benefits [USD, thousands] | 17,963 | 17,963 | 8,777 | 13,741 | 15,795 | 21,989 | 21,989 | 11,275 | ||||||||
| Lease Liabilities, Current Portion [USD, thousands] | 10,563 | 10,563 | 3,421 | 5,285 | 6,053 | 6,342 | 6,342 | 6,560 | ||||||||
| Credit Facility, Current Portion [USD, thousands] | - | - | - | - | - | - | - | 1,625 | ||||||||
| Total Current Liabilities [USD, thousands] | 105,456 | 105,456 | 63,723 | 65,175 | 96,714 | 103,168 | 103,168 | 93,758 | ||||||||
| Lease Liabilities, Net of Current Portion [USD, thousands] | 104,608 | 104,608 | 115,157 | 113,632 | 112,040 | 111,027 | 111,027 | 109,296 | ||||||||
| Liability Related to the Sale of Future Royalties [USD, thousands] | 268,326 | 268,326 | 273,692 | 280,938 | 336,031 | 341,361 | 341,361 | 346,776 | ||||||||
| Credit Facility, Net of Current Portion [USD, thousands] | - | - | - | - | - | 393,183 | 393,183 | 407,789 | ||||||||
| Total Long-Term Liabilities [USD, thousands] | 372,934 | 372,934 | 388,849 | 394,570 | 448,071 | 845,571 | 845,571 | 863,861 | ||||||||
| Additional Paid-in Capital [USD, thousands] | 1,300,395 | 1,300,395 | 1,320,356 | 1,768,866 | 1,786,304 | 1,806,000 | 1,806,000 | 1,846,842 | ||||||||
| Accumulated Other Comprehensive Income (Loss) [USD, thousands] | (3,222) | (3,222) | (1,255) | (1,095) | (987) | 4,750 | 4,750 | 4,137 | ||||||||
| Accumulated Deficit [USD, thousands] | (1,026,030) | (1,026,030) | (1,158,894) | (1,284,194) | (1,454,987) | (1,625,523) | (1,625,523) | (1,798,608) | ||||||||
| Total Arrowhead Pharmaceuticals, Inc. Stockholders’ Equity [USD, thousands] | 271,343 | 271,343 | 160,407 | 483,794 | 330,547 | 185,444 | 185,444 | 52,589 | ||||||||
| Noncontrolling Interest [USD, thousands] | 15,819 | 15,819 | 13,307 | 11,611 | 8,427 | 5,619 | 5,619 | 3,486 | ||||||||
| Total Noncontrolling Interest and Stockholders’ Equity [USD, thousands] | 287,162 | 287,162 | 173,714 | 495,405 | 338,974 | 191,063 | 191,063 | 56,075 | ||||||||
| Total Liabilities, Noncontrolling Interest and Stockholders’ Equity [USD, thousands] | 765,552 | 765,552 | 626,286 | 955,150 | 883,759 | 1,139,802 | 1,139,802 | 1,013,694 | ||||||||
| Cash Flow - Metric | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| Net Loss (USD, thousands) | - | - | - | - | (173,977.00) | (173,344.00) | (609,693) | (175,218) | ||||||||
| Stock-Based Compensation (USD, thousands) | - | - | - | - | 17,050.00 | 19,474.00 | 73,968 | 15,209 | ||||||||
| Depreciation and Amortization (USD, thousands) | - | - | - | - | 4,782.00 | 5,025.00 | 18,595 | 5,235 | ||||||||
| Accretion of Note Premiums/Discounts (USD, thousands) | - | - | - | - | 6,990.00 | (11,130.00) | (3,244) | (5,704) | ||||||||
| Realized Loss on Investments (USD, thousands) | - | - | - | - | 0.00 | 160.00 | 80 | - | ||||||||
| Non-Cash Interest Expense on Liability Related to Sale of Future Royalties (USD, thousands) | - | - | - | - | 5,093.00 | 5,330.00 | 23,035 | 5,415 | ||||||||
| Non-Cash Interest Expense on Credit Facility (USD, thousands) | - | - | - | - | - | - | 9,317 | 16,231 | ||||||||
| Other Operating Activities (USD, thousands) | - | - | - | - | - | - | (1,200) | 1,402 | ||||||||
| Net Cash Used in Operating Activities (USD, thousands) | - | - | - | - | (115,418.00) | (137,216.00) | (462,851) | (146,272) | ||||||||
| Purchases of Property and Equipment (USD, thousands) | - | - | - | - | (14,449.00) | (24,289.00) | (141,469) | (7,516) | ||||||||
| Purchases of Investments (USD, thousands) | - | - | - | - | (118,629.00) | (292,336.00) | (720,947) | (33,749) | ||||||||
| Proceeds from Sales and Maturities of Investments (USD, thousands) | - | - | - | - | 140,027.00 | 93,702.00 | 442,344 | 118,175 | ||||||||
| Net Cash Provided by Investing Activities (USD, thousands) | - | - | - | - | 6,949.00 | (222,923.00) | (420,072) | 76,910 | ||||||||
| Proceeds from the Exercises of Stock Options (USD, thousands) | - | - | - | - | 387.00 | 223.00 | 2,389 | 634 | ||||||||
| Proceeds from Issuance of Pre-Funded Warrants (USD, thousands) | - | - | - | - | - | - | - | 25,000 | ||||||||
| Proceeds from the Issuance of Common Stock, Net of Offering Costs (USD, thousands) | - | - | - | - | - | 0.00 | 429,265 | - | ||||||||
| Proceeds from the Sale of Future Royalties (USD, thousands) | - | - | - | - | - | 0.00 | 50,000 | - | ||||||||
| Proceeds from Credit Facility (USD, thousands) | - | - | - | - | - | - | 392,000 | - | ||||||||
| Payment of Debt Issuance Costs (USD, thousands) | - | - | - | - | - | - | (3,134) | (5,000) | ||||||||
| Net Cash Provided by Financing Activities (USD, thousands) | - | - | - | - | 50,387.00 | 389,089.00 | 870,520 | 20,634 | ||||||||
| Net Decrease / (Increase) in Cash, Cash Equivalents and Restricted Cash (USD, thousands) | - | - | - | - | (58,082.00) | 28,950.00 | (12,403) | (48,728) | ||||||||
| Effect of Exchange Rate on Cash, Cash Equivalents and Restricted Cash (USD, thousands) | - | - | - | - | (223.00) | 4,336.00 | 4,197 | (68) | ||||||||
| Income Taxes Paid (USD, thousands) | - | - | - | - | (48.00) | (682.00) | (3,744) | (11) | ||||||||
| Capital Expenditures Included in Accrued Expenses (USD, thousands) | - | - | - | - | (356.00) | (2,703.00) | 4,206 | 2,574 | ||||||||
| Debt Issuance Costs Included in Accrued Expenses (USD, thousands) | - | - | - | - | - | - | 5,000 | - | ||||||||
| Accounts Receivable (USD, thousands) | - | - | - | - | - | - | - | (2,500) | ||||||||
| Prepaid Expenses and Other Assets (USD, thousands) | - | - | - | (2,643) | (1,746) | (1,664) | (1,664) | (592) | ||||||||
| Accounts Payable (USD, thousands) | - | - | - | (8,402) | 2,785 | (5,536) | (5,536) | 3,069 | ||||||||
| Accrued Expenses (USD, thousands) | - | - | - | (11) | 13,086 | 32,117 | 32,117 | (7,691) | ||||||||
| Deferred Revenue (USD, thousands) | - | - | - | (866) | (866) | (866) | (866) | - | ||||||||
| Operating Lease, Net (USD, thousands) | - | - | - | 4,417 | 3,880 | 2,240 | 2,240 | (1,128) | ||||||||
| Cash, Cash Equivalents and Restricted Cash, Beginning of Period (USD, thousands) | - | - | - | 110,891 | 110,891 | 110,891 | 110,891 | 102,685 | ||||||||
| Cash, Cash Equivalents and Restricted Cash, End of Period (USD, thousands) | - | - | - | 127,704 | 69,399 | 102,685 | 102,685 | 53,889 | ||||||||
| Revenue by Segment - in Millions of USD | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| GSK | - | - | - | - | - | - | - | - | ||||||||
| - Milestone Payment | - | 15.00 | - | - | - | - | - | - | ||||||||
| Horizon | - | - | - | - | - | - | - | - | ||||||||
| Takeda | - | - | - | - | - | - | - | - | ||||||||
| Janssen | - | - | - | - | - | - | - | - | ||||||||
| Amgen | - | - | - | - | - | - | - | - | ||||||||
| Total Revenue | 16.1 | 240.735 | 3.55 | 0 | 0 | - | 3.551 | 2.5 | ||||||||
| KPIs - Metric (Unit, Scale) | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | FY 2024 | Q1 2025 |
| Number of patients dosed in a Phase 2 trial for daplusiran/tomligisiran (patients) | - | - | - | - | - | - | - | 5 | ||||||||
| Dose dependent reductions in circulating CFB protein for ARO-CFB with greater than 3 months duration (percentage) | - | - | - | - | - | - | - | 90 |